PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Stimulants and ADHD medications and psilocybin.

23 records in this group. 1 has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

23Records
1With human data

Overview

Reviewed 2026-10-14

Stimulant and ADHD medications have almost no published human data with psilocybin. Amphetamines and methylphenidate are sympathomimetic (adrenaline-like) and raise blood pressure and heart rate (amphetamine and methylphenidate prescribing information). Psilocybin has been shown to raise heart rate and blood pressure in some healthy adults (Becker 2022), so the two effects may add together.

One case report describes a hypertensive emergency, with chest pain, palpitations and headache, after psilocybin mushrooms were taken with tranylcypromine (an MAO inhibitor) and extended-release dextroamphetamine-amphetamine (Adderall XR). The authors attributed it to phenylethylamine in the mushrooms interacting with both drugs (Barnett 2024). Amphetamine prescribing information lists MAO inhibitors as a contraindication because of the risk of hypertensive crisis, with or without psilocybin.

Non-stimulant ADHD medications work differently. Atomoxetine and viloxazine block noradrenaline reuptake and can also raise heart rate and blood pressure. Clonidine and guanfacine lower blood pressure, and stopping them suddenly can cause rebound high blood pressure (atomoxetine, viloxazine, clonidine and guanfacine prescribing information). Each record lists the facts from that medication's own label.

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Also searched as stimulant · stimulants · ADHD medication · ADHD meds · ADHD

01 What the evidence covers

Best evidence available per medication
1Case reports
Case reports or online surveys
22No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • 4-FA (4-fluoroamphetamine)Evidence: No psilocybin data

    Other substances

    Not studied with psilocybin; this stimulant strongly raises blood pressure and heart rate, so adding to psilocybin's own rises is possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Amphetamine (including mixed amphetamine salts) · Adderall, Adderall XR, MydayisEvidence: Case reports

    ADHD (attention-deficit/hyperactivity disorder); Narcolepsy (immediate-release tablets)

    It may add to psilocybin's blood pressure, heart rate and anxiety rises; one case also involving the MAOI tranylcypromine had a hypertensive emergency.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Armodafinil · NuvigilEvidence: No psilocybin data

    Excessive sleepiness from obstructive sleep apnea (OSA), narcolepsy, or shift work disorder

    It may add to psilocybin's blood pressure, heart rate and anxiety effects. Its liver-enzyme effect skips the main routes that clear psilocybin.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Atomoxetine · StratteraEvidence: No psilocybin data

    ADHD (attention-deficit/hyperactivity disorder)

    It may add to psilocybin's blood pressure and heart rate rise. Also, it can cause psychotic or manic symptoms, even without that history.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Caffeine, guarana, pre-workoutEvidence: No psilocybin data

    Temporary fatigue or drowsiness (restoring alertness)

    Its caffeine raises blood pressure, heart rate and anxiety, which may add to psilocybin's rise. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Centanafadine · SimtriyoEvidence: No psilocybin data

    ADHD (attention-deficit/hyperactivity disorder) in adults and children 6 years and older

    As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety. Its label also warns of serotonin syndrome.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Clonidine · Catapres, Kapvay, Onyda XREvidence: No psilocybin data

    High blood pressure; ADHD (attention-deficit/hyperactivity disorder; extended-release)

    It may blunt psilocybin's blood pressure rise but has no known direct interaction. Stopping it suddenly after regular use can cause rebound high blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • CocaineEvidence: No psilocybin data

    Other substances

    Its rise in blood pressure and heart rate may add to psilocybin's. Also, it can cause heart rhythm problems, seizures and paranoia.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Dexmethylphenidate · Focalin, Focalin XREvidence: No psilocybin data

    Attention-deficit/hyperactivity disorder (ADHD)

    As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Dextroamphetamine · Dexedrine, Zenzedi, XelstrymEvidence: No psilocybin data

    Narcolepsy; ADHD (attention-deficit/hyperactivity disorder)

    As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, it can cause psychotic or manic symptoms.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • DMAA / DMHA stimulantsEvidence: No psilocybin data

    Supplements and over the counter

    Its blood pressure and heart rate rise may add to psilocybin's. Also, it is linked to heart rhythm problems, heart attack and seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Guanfacine · Intuniv, TenexEvidence: No psilocybin data

    Attention-deficit/hyperactivity disorder (ADHD) (extended-release); High blood pressure (immediate-release)

    It may dampen psilocybin's blood pressure rise and can cause dizziness on standing. Stopping it suddenly after regular use can cause rebound high blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • KhatEvidence: No psilocybin data

    Other substances

    Not studied with psilocybin; chewing it raises blood pressure and heart rate, as psilocybin does; heavy use is linked to psychosis-like symptoms and heart attacks.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Lisdexamfetamine · VyvanseEvidence: No psilocybin data

    Attention-deficit/hyperactivity disorder (ADHD); Binge eating disorder (moderate to severe, adults)

    It may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, it can worsen psychotic symptoms.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Methamphetamine · DesoxynEvidence: No psilocybin data

    Attention-deficit/hyperactivity disorder (ADHD)

    It may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, it can cause psychotic or manic symptoms.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Methylphenidate d,l · Ritalin, Concerta, RelexxiiEvidence: No psilocybin data

    Attention-deficit/hyperactivity disorder (ADHD); Narcolepsy (immediate-release Ritalin)

    As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Modafinil · ProvigilEvidence: No psilocybin data

    Excessive sleepiness from narcolepsy; Excessive sleepiness from obstructive sleep apnea

    Its stimulant-like effects on blood pressure, heart rate and anxiety may add to psilocybin's.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Phentermine · AdipexEvidence: No psilocybin data

    Obesity (short-term, with diet, exercise and behavior change)

    Not studied with psilocybin; it raises blood pressure and heart rate, so an added rise is possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Phentermine–topiramate · QsymiaEvidence: No psilocybin data

    Weight management in obesity (adults and ages 12+) or adult overweight with a weight-related condition (with diet and exercise)

    Phentermine's rise in blood pressure and heart rate may add to psilocybin's. Stopping it suddenly after regular use can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Serdexmethylphenidate–d-MPH · AzstarysEvidence: No psilocybin data

    Attention-deficit/hyperactivity disorder (ADHD)

    As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Solriamfetol · SunosiEvidence: No psilocybin data

    Excessive daytime sleepiness in narcolepsy; Excessive daytime sleepiness in obstructive sleep apnea (OSA)

    It may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, its label describes possible psychiatric symptoms.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Synthetic cathinones ("bath salts")Evidence: No psilocybin data

    Other substances

    Not studied with psilocybin; these amphetamine-like stimulants are linked to fast heartbeat, high blood pressure, overheating, seizures, psychosis and serotonin syndrome.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Viloxazine · QelbreeEvidence: No psilocybin data

    Attention-deficit/hyperactivity disorder (ADHD)

    It raises blood pressure and heart rate, which may add to psilocybin's rise. Also, its label warns of suicidal thoughts, mania and sleepiness.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
21Raises blood pressure or heart rate
17Psychiatric reactions
10Withdrawal or rebound if stopped abruptly
8Serotonergic
7Lowers seizure threshold or carries seizure risk
4Sedating or CNS depressant
3Lowers blood pressure or causes orthostasis
3Speeds up drug metabolism
2Liver injury
1QT-prolonging

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 16 of the 23 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
7Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
7Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
3Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689.
1Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
1Cohen PA, Travis JC, Keizers PHJ, Deuster P, Venhuis BJ. Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol (Phila) 2018;56(6):421-426.
1de Sousa Fernandes Perna EB, Theunissen EL, Dolder PC, et al. Safety profile and neurocognitive function following acute 4-fluoroamphetamine (4-FA) administration in humans. Front Pharmacol 2018;9:713.
1Gerostamoulos D, Glowacki L, Pricone M, et al. Fatal intoxications from a combination of 4-fluoroamphetamine and 25C-NBOMe. J Anal Toxicol 2023;47(2):191–196.
1Gresnigt FMJ, Snik A, Franssen EJF, et al. 4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: a retrospective analysis. J Am Coll Emerg Physicians Open 2022;3(5):e12813.
1Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006;6:6.
1Kuypers KPC, De Sousa Fernandes Perna EB, Theunissen EL, et al. A first-in-man study with 4-fluoroamphetamine demonstrates it produces a mild psychedelic state. J Psychoactive Drugs 2019;51(3):225–235.
1Luethi D, Walter M, Zhou X, et al. Para-halogenation affects monoamine transporter inhibition properties and hepatocellular toxicity of amphetamines and methcathinones. Front Pharmacol 2019;10:438.
1Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8(1):33–42.
1Schifano F, Chiappini S, Miuli A, et al. New psychoactive substances (NPS) and serotonin syndrome onset: a systematic review. Exp Neurol 2021;339:113638.
1Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
1Toennes SW, Schneider D, Pogoda W, et al. Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. Drug Test Anal 2019;11(7):1028–1034.

Related classes

Records reviewed 2026-10-03 to 2026-11-02. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25